Premium
Determining the optimal dose and schedule of sunitinib
Author(s) -
Suarez Cristina,
Rini Brian I.
Publication year - 2011
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.26426
Subject(s) - medicine , sunitinib , schedule , intensive care medicine , cancer , computer science , operating system
Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors. In this issue, Barrios et al present a study in which 120 treatment‐naive patients with metastatic RCC were enrolled in a single‐arm, open‐label, phase 2 trial of continuous once‐daily sunitinib. This study and other data provide insight into optimal dosing of sunitinib in metastatic RCC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom